Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 141 | 40% |
| 2020 | 2 | 128 | 43% |
| 2021 | 3 | 146 | 48% |
| 2022 | 5 | 175 | 51% |
| 2023 | 3 | 179 | 55% |
| 2024 | 6 | 309 | 57% |
| 2025 from claims | – | 241 195–283 | 58% |
| 2026 forecast | – | 262 205–329 | 58% |
| 2027 forecast | – | 285 211–377 | 59% |
| 2028 forecast | – | 310 219–428 | 60% |
| 2029 forecast | – | 336 229–482 | 60% |
| 2030 forecast | – | 365 239–542 | 61% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Missouri; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 17 | 594+15%/yr | +15%/yr | 0.4 | 0% | 1,210 in 2030+13%/yr |
| Ohio | 15 | 485+7.7%/yr | +7.7%/yr | 0.4 | 0% | 720 in 2030+6.9%/yr |
| Michigan | 7 | 386+9.3%/yr | +9.3%/yr | 0.5 | 0% | 640 in 2030+8.7%/yr |
| Minnesota | 8 | 304+10%/yr | +10%/yr | 0.7 | 0% | 720 in 2030+16%/yr |
| Indiana | 8 | 202+15%/yr | +15%/yr | 0.3 | 0% | 430 in 2030+13%/yr |
| Iowa | 5 | 166+11%/yr | +11%/yr | 0.4 | 0% | 360 in 2030+14%/yr |
| Wisconsin | 2 | 154+1.5%/yr | +1.5%/yr | 0.3 | 0% | 470 in 2030+20%/yr |
| Kansas | 5 | 146+15%/yr | +15%/yr | 0.4 | 0% | 210 in 2030+6.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 12 | 310+5.1%/yr | +5.1%/yr | 0.51.3× | 0% | 380 in 2030+3.2%/yr |
| DBS & VNS | 3 | 276−9.1%/yr | −9.1%/yr | 0.41.3× | 0% | 290 in 2030+0.5%/yr |
| CSF shunts | 0 | 137−5.5%/yr | −5.5%/yr | 0.21.2× | 0% | 180 in 2030+4.6%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Illinois
Neurolutions leads with 46% of company spending on these surgeons in 2025, +46 pts on 2024.
In 2025, 9 companies reported engagement with Missouri’s surgeons worth $141K in consulting, speaking, meals and travel tied to these products, about $24K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.